Truist Securities Maintains Buy on Gilead Sciences, Lowers Price Target to $156

Benzinga · 07/07 12:23
Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and lowers the price target from $157 to $156.